Onderneming Capricor Therapeutics Inc Nasdaq
Aandelen
US14070B1017
Biotechnologie & Medisch Onderzoek
Vakgebied
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Transformative Cell and Exosome-based Therapeutics
100,0
%
| 3 | 100,0 % | 25 | 100,0 % | +886,81% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 3 | 100,0 % | 25 | 100,0 % | +886,81% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Linda Marbán
CEO | Chief Executive Officer | 60 | 20-11-13 |
Anthony Bergmann
DFI | Director of Finance/CFO | 38 | 20-11-13 |
Kristi Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-21 |
Karen Krasney
LAW | General Counsel | 71 | 01-01-12 |
General Counsel | 71 | 28-02-15 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Philip Gotwals
BRD | Director/Board Member | 61 | 21-07-23 |
Earl Collier
BRD | Director/Board Member | 76 | 20-11-13 |
George Dunbar
BRD | Director/Board Member | 77 | 20-11-13 |
David Musket
BRD | Director/Board Member | 66 | 20-11-13 |
Frank Litvack
CHM | Chairman | 68 | 01-01-12 |
Karimah Es Sabar
BRD | Director/Board Member | 66 | 23-07-21 |
Linda Marbán
CEO | Chief Executive Officer | 60 | 20-11-13 |
Paul Auwaerter
BRD | Director/Board Member | 62 | 13-07-23 |
Michael Kelliher
BRD | Director/Board Member | 47 | 01-09-23 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 31 502 972 | 28 874 629 ( 91,66 %) | 0 | 91,66 % |
Bedrijfsgegevens
Capricor Therapeutics, Inc.
10865 Road to the Cure Suite 150
92121, San Diego
+858 727 1755
http://www.capricor.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
-1,65% | 104 mld. | |
+6,75% | 97,47 mld. | |
+5,71% | 22,25 mld. | |
-12,60% | 21,68 mld. | |
-9,70% | 18,2 mld. | |
-39,98% | 17,02 mld. | |
-10,17% | 16,36 mld. | |
+6,12% | 14,39 mld. | |
+35,47% | 12,37 mld. |